<DOC>
	<DOCNO>NCT02853604</DOCNO>
	<brief_summary>High-risk locally advance carcinoma cervix ( HRLACC ) follow concurrent chemotherapy radiation therapy . This group patient significant unmet need . The estimated probability disease recurrence death within 4 year diagnosis 50 % prognosis grave experience recurrence . The purpose study compare disease free survival ( DFS ) ADXS11-001 placebo administer follow CCRT curative intent subject HRLACC .</brief_summary>
	<brief_title>Study ADXS11-001 Subjects With High Risk Locally Advanced Cervical Cancer</brief_title>
	<detailed_description>This double-blind , placebo-controlled randomize study ADXS11 001 administer adjuvant set completion cisplatin-based CCRT subject locally advanced cervical cancer high risk recurrence ( HRLACC ) , death . All eligible subject receive CCRT administer curative intent accord institutional/national guideline well meet minimum standard define protocol . Subjects must initiate Screening period within 10 week completion CCRT . Baseline radiographic assessment clinical laboratory assessment must complete longer 28 day prior 3 day prior first study treatment infusion , respectively . Eligible subject randomize 1:2 receive either placebo ADXS11-001 . Subjects receive 1 infusion study treatment administer every 3 week 3 dos first 3 month . Thereafter , subject receive study treatment every 8 week total 5 dos disease recurrence . Subjects receive 7-day course oral antibiotic placebo start 72 hour follow completion study treatment administration . An interim analysis perform least one-half number DFS event require full maturity study .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<criteria>Subjects must biopsy confirmed diagnosis squamous cell , adenocarcinoma , adenosquamous carcinoma cervix . Histologic confirmation original primary tumor require . Subjects must receive definitive therapy curative intent , consist least 4 week treatment cisplatin minimum 40Gy external beam radiation therapy ( EBRT ) . Have performance status 0 1 GOG performance scale Demonstrate adequate organ function Has achieve diseasefree status completion CCRT administer curative intent . Has FIGO Stage IVB Has histologies squamous cell , adenocarcinoma , adenosquamous carcinoma cervix . Has implant medical device ( ) pose high risk colonization and/or easily remove ( e.g. , prosthetic joint , artificial heart valve , pacemaker , orthopedic screw ( ) , metal plate ( ) , bone graft ( ) , exogenous implant ( ) ) . Has contraindication ( sensitivity allergy ) trimethoprim/sulfamethoxazole ampicillin . Has undergone previous hysterectomy define removal entire uterus hysterectomy part initial cervical cancer therapy . NOTE : Women partial/subtotal hysterectomy eligible participate study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>